Building a Spravato Treatment Program: REMS, Billing, and Operations for Behavioral Health Agencies

Spravato (esketamine) is one of the most meaningful advances in the treatment of major depressive disorder — and one of the most operationally demanding services a behavioral health agency can add. It is not a medication you prescribe. It is a program you build.

Agencies that succeed with Spravato treat it as a service line with its own compliance framework, staffing model, physical space, and revenue cycle — not as an add-on to existing medication management. This guide walks through what that build actually looks like, based on what we have seen work with agencies standing these programs up.

Why agencies add Spravato — and why some stall out

The clinical case is strong. For patients with treatment-resistant depression — two or more adequate antidepressant trials without response — esketamine offers a meaningful chance at response and remission where little else has moved the needle. For agencies, it also serves patients who would otherwise cycle through referrals, ED visits, and failed med trials.

The stall-out pattern is consistent: an agency orders the drug, enrolls one prescriber, and then discovers the REMS requirements, the two-hour observation, the space requirements, and the prior authorization burden — and the program sits dormant for six months. The difference between programs that launch and programs that stall is almost always operational planning done before the first dose, not after.

Step 1: REMS certification is the gate

Spravato is only available through a restricted Risk Evaluation and Mitigation Strategy (REMS) program because of its risks: sedation, dissociation, respiratory depression, and abuse potential. Before a single dose is administered:

- The **healthcare setting** must be REMS-certified — not just the prescriber. This requires attesting to safe-use conditions, designating an authorized representative, and committing to the monitoring requirements. - **Every patient** must be enrolled in the REMS patient registry before their first treatment. - Every administration must be **documented and reported** through the REMS system, including the Patient Monitoring Form after each session.

Budget real time for this. The certification itself is not slow; building the internal workflows that satisfy it is where agencies underestimate the work. Your policies need to cover chain of custody for a Schedule III controlled substance, storage and reconciliation, adverse event reporting, and diversion prevention — and REMS-certified settings can be inspected.

Step 2: Space, staffing, and the two-hour observation

Every Spravato administration requires a minimum **two-hour observation period** by a healthcare professional, with blood pressure checks before dosing, at 40 minutes, and as clinically indicated, plus assessment for readiness for discharge at the end. Patients cannot drive until the next day after a restful sleep.

That requirement drives your physical plant and your staffing model:

- **Space.** You need a calm, monitored treatment area where patients can recline — recliners or adjustable chairs work well. One or two treatment chairs is a realistic starting point; throughput math (two sessions per chair per day, with turnover time) determines when expansion makes sense. - **Staffing.** Monitoring can be performed by appropriately credentialed clinical staff under your state scope-of-practice rules — many programs use RNs or LPNs with prescriber availability per your protocols and state requirements. The prescriber does not have to sit in the room, but your written protocol must define availability, escalation, and emergency response. - **Scheduling.** Twice-weekly induction for the first four weeks, then weekly, then weekly or every-other-week maintenance — each patient occupies a chair for roughly two and a half hours. Model your chair capacity against your patient census before you commit to a caseload target.

The agencies that run efficient programs treat the observation window as a clinical touchpoint, not dead time: mood assessments, PHQ-9 tracking, and care coordination all happen during monitoring.

Step 3: The revenue cycle — where most programs win or lose

Spravato economics live or die on two decisions: how the drug is acquired and how the administration is billed.

**Buy-and-bill vs. pharmacy benefit.** Under buy-and-bill, your agency purchases the medication through an authorized specialty distributor and bills the patient's medical benefit for the drug (HCPCS S0013) plus administration and monitoring services. The alternative is routing the drug through a specialty pharmacy under the patient's pharmacy benefit, in which case you bill only for the professional services. Buy-and-bill offers more control and better margin, but it requires working capital — the drug is expensive, and you are floating the cost until the claim pays.

**Prior authorization is the bottleneck.** Nearly every payer requires prior authorization documenting treatment-resistant depression: typically two or more failed antidepressant trials at adequate dose and duration, plus a current adequate trial. Build a standardized PA packet with your documentation checklist, the patient's trial history, and concurrent oral antidepressant documentation (required for the TRD indication). Agencies that assign one person to own PAs and track every submission get approvals in days; agencies that don't get denials for missing trial documentation.

**Bill the observation correctly.** The two-hour monitoring is billable work. Know your payer's position on prolonged services, observation codes, and what the REMS-required monitoring supports under medical-necessity documentation, and build your charge capture around it from day one.

**Verify benefits before induction.** Coverage policies differ by payer and change frequently. A benefit verification script that confirms the drug pathway (medical vs. pharmacy benefit), PA requirements, and patient cost share prevents the worst outcome in this program: a patient four sessions in who can no longer afford to continue.

Step 4: Documentation and clinical infrastructure

A Spravato program needs its own documentation set, distinct from standard psychiatry notes:

- REMS enrollment and Patient Monitoring Forms - Spravato-specific informed consent covering sedation, dissociation, driving restrictions, and the REMS program - Treatment-resistant depression documentation template (prior trial history, doses, durations, outcomes) - Treatment and observation flow sheet with vital signs and adverse event fields - Induction/maintenance treatment plan with response tracking (PHQ-9 or MADRS at defined intervals) - Transportation attestation and discharge-readiness criteria - Controlled substance handling, storage, count, and waste policies

This paperwork is what a REMS inspection, a payer audit, or a malpractice review will ask for first. Agencies that assemble it during the build phase pass these reviews; agencies that retrofit it after the fact do not enjoy the experience.

Step 5: Patient flow and program sustainability

Referral sources for TRD are everywhere once you look: psychiatrists with failed med trials, primary care, partial hospitalization and IOP step-downs, and community mental health centers without Spravato capacity. A simple referral intake form and a 48-hour response commitment builds referral loyalty fast.

Inside the program, track the numbers that predict sustainability: PA approval rate and turnaround time, chair utilization, no-show rate (induction adherence is the single biggest clinical variable), days from referral to first dose, days in AR by payer, and response/remission rates at 8–12 weeks. That last metric is the one that wins payer conversations and new referral relationships.

How PracticeSync Pro helps agencies build and facilitate these programs

This is work we do directly. PracticeSync Pro has helped behavioral health agencies build Spravato service lines from the ground up — the REMS certification workflow, the policy and documentation set, the buy-and-bill revenue cycle, the PA process, and the staffing and scheduling model that makes the chair economics work.

We also facilitate established programs: cleaning up billing leakage, tightening prior authorization approval rates, preparing for REMS inspections, and scaling from two chairs to a full service line. Whether an agency is evaluating Spravato for the first time or fixing a program that stalled, the pattern is the same — get the operational foundation right and the clinical program follows.

If you're standing up a Spravato program, our Spravato Forms Kit includes the unbranded, editable documentation set — consent forms, monitoring flow sheets, treatment plan templates, and policy language — so your team starts from a complete foundation instead of a blank page.

*This article is educational and not legal, billing, or clinical advice. REMS requirements, payer policies, and scope-of-practice rules vary; verify current requirements with the REMS program and your payers.*